Clinical trials: Epidermolysis Bullosa Simplex Kobner
Generalized Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
- Trial name
- EBShield (NCT06073132)
- Testing
- AC-203, Vehicle
- Where
- 30 sites in United States, Australia and 16 more
- Volunteers
- 80 people
- Sponsor
- TWi Biotechnology, Inc.